Abstract
The evolution of coagulation and fibrinolysis has not been thoroughly evaluated in allogeneic SCT. In this pilot study, we characterized the adaptive mechanisms of coagulation and fibrinolysis during allogeneic SCT and 3-month follow-up and studied possible associations with outcome, including acute GVHD. Thirty patients underwent SCT for a haematological malignancy after myeloablative conditioning. Nineteen patients received the transplant from an HLA-identical sibling and 11 from an unrelated donor. GVHD prophylaxis consisted of CYA and MTX, with methylprednisolone in sibling transplants. Serial coagulation and fibrinolytic activity markers were assessed, including prothrombin fragments 1+2 (F1+2), thrombin time, D-dimer, tissue-type plasminogen-activator (tPA) and plasminogen-activator inhibitor (PAI-1). Early during conditioning therapy, F1+2 and D-dimer increased threefold indicating thrombin generation and fibrin turnover. TPA activity peaked before engraftment, concurring with diminished PAI-1. At 10 days after transplantation shortened thrombin time (<15 s), F1+2 exceeding 0.7 nmol/L and PAI-1 3.0 IU/mL were associated with the development of GVHD. In conclusion, early maladaptation, that is, upregulated thrombin generation and inhibition of fibrinolysis, occurred in one-third of the SCT patients associating with the development of GVHD, a finding suggesting an interplay between coagulation and immunology during SCT.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Pettitt AR, Clark RE . Thrombotic microangiopathy following bone marrow transplantation. Bone Marrow Transplant 1994; 14: 495–504.
Van der Plas RM, Schiphorst ME, Huizinga EG, Hené RJ, Verdonck LF, Sixma JJ et al. Von Willebrand Factor Proteolysis is deficient in classic, but not in bone marrow transplantation-associated, thrombotic thrombocytopenic purpura. Blood 1999; 93: 3798–3802.
Ruutu T, Barosi G, Benjamin RJ, Benjamin RJ, Clark RE, George JN et al. European Group for Blood and Marrow transplantation; European LeukemiaNet. Diagnostic criteria for hematopoietic stem cell transplant—associated microangiopathy: results of a consensus process by an International Working Group. Haematologica 2007; 92: 95–100.
Carreras E . Veno-occlusive disease of the liver after hemopoietic cell transplantation. Eur J Haematol 2000; 64: 281–291.
Cahill RA, Spitzer TR, Mazumder A . Marrow engraftment and clinical manifestations of capillary leak syndrome. Bone Marrow Transplant 1996; 18: 177–184.
Testa S, Manna A, Porcellini A, Maffi F, Morstabilini G, Denti N et al. Increased plasma level of vascular endothelial glycoprotein thrombomodulin as an early indicator of endothelial damage in bone marrow transplantation. Bone Marrow Transplant 1996; 18: 383–388.
Biedermann BC . Vascular endothelium and graft-versus-host disease. Best Pract Res Clin Haematol 2008; 21: 129–138.
Holler E, Kolb HJ, Möller A, Kempeni J, Liesenfeld S, Pechumer H et al. Increased serum levels of tumor necrosis factor α precede major complications of bone marrow transplantation. Blood 1990; 75: 1011–1016.
Woywodt A, Scheer J, Hambach L, Buchholz S, Ganser A, Haller H et al. Circulating endothelial cells as a marker of endothelial damage in allogeneic hematopoietic stem cell transplantation. Blood 2004; 103: 3603–3605.
Aird WC . Endothelial-platelet interplay in sepsis. Hematol Am Soc Hematol Educ Program 2003, 497–503.
Pihusch R, Wegner H, Salat C, Pihusch M, Holler E, Kolb HJ et al. Flow cytometric findings in platelets of patients following allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2002; 30: 381–387.
Nürnberger W, Michelmann I, Burdach S, Göbel U . Endothelial dysfunction after bone marrow transplantation: Increase of soluble thrombomodulin and PAI-1 in patients with multiple transplant-related complications. Ann Hematol 1998; 76: 61–65.
Brown SA, Davies SV, Fegan C, West R, Giddings J, Whittaker J et al. Haemostatic and fibrinolytic responses to bone marrow transplantation. Br J Haematol 1999; 104: 468–474.
Catani L, Gugliotta L, Mattioli Belmonte M, Vianelli N, Gherlinzoni F, Miggiano MC et al. Hypercoagulability in patients undergoing autologous or allogeneic BMT for hematological malignancies. Bone Marrow Transplant 1993; 12: 253–259.
Villalün L, Avello AG, César J, Odriozola J, Lüpez J, Oteyza JP et al. Is veno-occlusive disease a specific syndrome or the exacerbation of physiopathologic hemostatic changes in hematopoietic stem cell transplantation (HSCT)? Thromb Res 2000; 99: 439–446.
Tanikawa S, Mori S, Ohhashi K, Akiyama H, Sasaki T, Kaku H et al. Predictive markers for hepatic veno-occlusive disease after hematopoietic stem cell transplantation in adults: a prospective single center study. Bone Marrow Transplant 2000; 26: 881–886.
Ruutu T, Volin L, Parkkali T, Juvonen E, Elonen E . Cyclosporine, methotrexate, and methylprednisolone compared with cyclosporine and methotrexate for the prevention of graft-versus-host disease in bone marrow transplantation from HLA-identical sibling donor: a prospective randomized study. Blood 2000; 96: 2391–2398.
Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J et al. 1994 Consensus conference on Acute GVHD Grading. Bone Marrow Transplant 1995; 15: 825–828.
Peltonen S, Lassila R, Rossi P, Salenius JP, Lepäntalo M . Blood coagulation and fibrinolysis activation during sudden arterial occlusion of lower extremities-an association with ischemia and patient outcome. Thromb Haemost 1995; 74: 1442–1446.
Stephens R, Leung KC, Pöllänen J, Salonen EM, Vaheri A . Microplate immunocapture assay for plasminogen activators and their specific inhibitors. J Immunol Methods 1987; 105: 245–251.
Brandão LR, Kletzel M, Boulad F, Kurtzberg J, Maloney K, Fligman I et al. A prospective longitudinal multicenter study of coagulation in pediatric patients undergoing allogeneic stem cell transplantation. Pediatr Blood Cancer 2008; 50: 1240–1246.
Heissig B, Lund LR, Akimyama H, Ohki M, Morita Y, Rømer J et al. The plasminogen fibrinolytic pathway is required for hematopoietic regeneration. Cell Stem Cell 2007; 1: 658–670.
Weber M, Kröger N, Langer F, Hansen A, Zabelina T, Eifrig B et al. Non-overt disseminated intravascular coagulation in patients during treatment with antithymocyte globulin for unrelated allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2003; 31: 817–822.
Levi M, de Jonge E, van der Poll T, ten Cate H . Disseminated Intravascular Coagulation. Thromb Haemost 1999; 82: 695–705.
Hill GR, Crawford JM, Cooke KR, Brinson YS, Pan L, Ferrara JL . Total body irradiation and acute graft-versus-host disease: the role of gastro-intestinal damage and inflammatory cytokines. Blood 1997; 90: 3204–4213.
Pihusch R, Höhnberg B, Salat C, Pihusch M, Hiller E, Kolb HJ . Platelet flow cytometric findings in patients undergoing conditioning therapy for allogeneic hematopoietic stem cell transplantation. Ann Hematol 2002; 81: 454–461.
Siljander P, Carpen O, Lassila R . Platelet-derived microparticles associate with fibrin during thrombosis. Blood 1996; 87: 4651–4663.
Lindemann S, Tolley ND, Dixon DA, McIntyre TM, Prescott SM, Zimmerman GA et al. Activated platelets mediate inflammatory signalling by regulated interleukin 1β synthesis. J Cell Biol 2001; 154: 485–490.
Ardoin SP, Shanahan JC, Pisetsky DS . The role of microparticles in inflammation and thrombosis. Scand J Immunol 2007; 66: 159–165.
Acknowledgements
We thank Professor Seppo Sarna for his expertise and help in the statistical analysis, and laboratory technician Ellen Saarela for her help in the laboratory analyses.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Pinomäki, A., Volin, L., Joutsi-Korhonen, L. et al. Early thrombin generation and impaired fibrinolysis after SCT associate with acute GVHD. Bone Marrow Transplant 45, 730–737 (2010). https://doi.org/10.1038/bmt.2009.227
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2009.227
Keywords
This article is cited by
-
Potentially life-threatening coagulopathy associated with simultaneous reduction in coagulation and fibrinolytic function in pediatric acute leukemia after hematopoietic stem-cell transplantation
International Journal of Hematology (2017)
-
Inhibition of plasmin attenuates murine acute graft-versus-host disease mortality by suppressing the matrix metalloproteinase-9-dependent inflammatory cytokine storm and effector cell trafficking
Leukemia (2015)
-
Reduced IL-35 levels are associated with increased platelet aggregation and activation in patients with acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation
Annals of Hematology (2015)